2010 Past Program
First International Conference on Cancer and the Heart
November 3-4, 2010
Wednesday, November 3
| 7:00 a.m. | Registration and continental breakfast |
| 8:00-8:25 a.m. | Welcome Edward T.H. Yeh, M.D., MD Anderson Cancer Center, Houston, TX James T. Willerson, M.D., President and Medical Director, Texas Heart Institute at St. Luke’ Episcopal Hospital, Houston, TX Raymond DuBois, M.D., Ph.D., Provost and Executive Vice President, MD Anderson Cancer Center Houston, TX |
| 8:20-9:40 a.m. | Session I: Defining clinical problems Moderator: Michael S. Ewer, M.D., J.D. |
| 8:20-8:40 a.m. | Cardiac dysfunction following cancer treatment: are the clinical enigmas falling into place? Michael S. Ewer, M.D., J.D. |
| 8:40-9:00 a.m. | Anthracyclines for adjuvant treatment in breast cancer: Recommendation from the heart Sandra M. Swain, M.D. |
| 9:00-9:20 a.m. | Long-term follow-up and long-term implications of cardiotoxic treatment of cancer Thomas M. Suter, M.D. |
| 9:20-9:40 a.m . | Panel discussion Joseph R. Carver, M.D., Michael S. Ewer, M.D., J.D., Thomas M. Suter, M.D., Sandra M. Swain, M.D. |
| 9:40-10:00 a.m . | Break |
| 10:00-12:05 a.m. | Session II: Basic mechanisms Moderator: Edward T.H. Yeh, M.D. |
| 10:00-10:25 a.m. | Identification of the primary target of doxorubicin-induced cardiotoxicity Edward T.H. Yeh, M.D. |
| 10:25-10:50 a.m. | New insights on mechanisms of cardiotoxicity Peter Liu, M.D. |
| 10:50-11:15 a.m. | Mechanism of TKI-induced cardiotoxicity Thomas L. Force, M.D. |
| 11:15-11:40 a.m. | PDGFR/VEGFR in the pathogenesis of sutent-induced HTN and cardiomyopathy Aarif Y. Khakoo, M.D. |
| 11:40-12:05 p.m. | An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic Gabriel Lopez-Berestein, M.D. |
12:05-1:00 p.m. 12:25-12:45 p.m. | Lunch Lunch presentation: Heart failure to heart success: A patient’s story, the MD Anderson experience Jean-Bernard Durand, M.D. |
| 1:00-2:35 p.m. | Session III: LV Dysfunction Moderator: Douglas B. Sawyer, M.D., Ph.D. |
| 1:00-1:20 p.m. | Biomarkers in the prediction and management of chemotherapy-induced cardiotoxicity Daniela Cardinale M.D., Ph.D. |
| 1:20-1:40 p.m. | Heart failure in cancer patients unrelated to chemotherapy Douglas B. Sawyer, M.D., Ph.D. |
| 1:40-2:00 p.m. | Effects of Aerobic Training to Improve Cardiovascular Function and Prevent Cardiac Remodeling After Cytotoxic Therapy in Early Breast Cancer Lee W. Jones, Ph.D. |
| 2:00-2:20 p.m. | Bridging the symptom management gap in cancer patients with heart failure Anecita Fadol, Ph.D. |
| 2:20-2:35 p.m. | Panel discussion Daniela Cardinale M.D., Ph.D., Anecita Fadol, Ph.D., Lee W. Jones, Ph.D., Douglas B. Sawyer, M.D., Ph.D. |
| 2:35-2:50 p.m. | Break |
| 2:50-4:55 p.m. | Session IV: Basic mechanisms Moderator: Tom Force, M.D |
| 2:50- 3:15 p.m. | Cancer-induced cardiomyopathy Leslie A. Leinwand, Ph.D. |
| 3:15-3:40 p.m. | Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism HQ Han, M.D., Ph.D. |
| 3:40-4:05 p.m. | Autophagy in cardiac plasticity and disease Joseph A. Hill, M.D., Ph.D. |
| 4:05-4:30 p.m. | Cardio-regenerative small-molecules Jay W. Schneider, M.D., Ph.D. |
| 4:30-4:55 p.m. | Role of cardiac progenitor cells in doxorubicin-induced cardiotoxicity Jan Kajstura, Ph.D. |
| 4:55-5:55 p.m. | Session V: Radiation Moderator: S. Wamique Yusuf, M.D. |
| 4:55-5:25 p.m. | Radiation therapy-induced cardiotoxicity Sarah C. Darby, Ph.D. |
| 5:25-5:45 p.m. | Clinical effects of radiation therapy S. Wamique Yusuf, M.D. |
| 5:45-5:55 p.m. | Panel discussion Sarah C. Darby, Ph.D., David Cutter, M.B., S. Wamique Yusuf, M.D. |
Thursday, Nov. 4, 2010
| 7:00 a.m. | Registration and continental breakfast |
| 8:00-8:45 a.m. | Session VI: Cardiologists' role in clinical trials Panel discussion Moderator: Charles E. Geyer Jr., M.D. Daniela Cardinale M.D., Ph.D., Michael S. Ewer, M.D., J.D., Giorgio Minotti, M.D., Apostolia-Maria Tsimberidou, M.D., Ph.D. |
| 8:45-10:00 a.m. | Session VII: Thrombocytopenia and hypercoagulability Moderators: Cezar Iliescu, M.D. and Jean-Bernard Durand, M.D. |
| 8:45-9:05 a.m. | Mechanisms of platelet-dependent hemostasis versus thrombosis Michael Kroll, M.D. |
| 9:05-9:25 a.m. | Endovascular procedures in cancer patients with chronic thrombocytopenia Cezar Iliescu, M.D. |
| 9:25-9:45 a.m. | Evaluating the biological efficacy of antiplatelet medication in cancer patients: genotype or phenotype? Jean-Bernard Durand, M.D. |
| 9:45-10:00 a.m. | Panel discussion Jean-Bernard Durand, M.D., Cezar Iliescu, M.D., Michael Kroll, M.D. |
| 10:00-10:20 a.m. | Break |
| 10:20-12:00 p.m. | Session VIII: Imaging Moderator: Jose A. Banchs, M.D. |
| 10:20-10:40 a.m. | Echocardiography in the prediction of left ventricular function Juan Carlos Plana, M.D. |
| 10:40-11:00 a.m. | Use of 2-D based strain for surveillance of chemotherapeutic induced cardiotoxicity in a pediatric population John Lynn Jefferies, M.D., M.P.H. |
| 11:00-11:20 a.m. | MRI as a tool to predict chemotherapy-induced cardiotoxicity W. Gregory Hundley, M.D. |
| 11:20-12:00 p.m. | Case presentations/panel discussion Jose A. Banchs, M.D., Iyad Daher, M.D., W. Gregory Hundley, M.D., John Lynn Jefferies, M.D., M.P.H., Juan Carlos Plana, M.D. |
| 12:00-1:00 p.m. | Lunch Session IX: Poster Session |
| 1:00-2:10 p.m. | Session X: Cardiac tumors: Diagnosis, imaging and treatment Moderator: Monika J. Leja, M.D. |
| 1:00-1:20 p.m. | Introduction to cardiac tumors: Imaging with computed tomography and echocardiography Monika J. Leja, M.D. |
| 1:20-1:40 p.m. | Imaging of cardiac tumors with cardiac MRI Dipan J. Shah, M.D. |
| 1:40-2:00 p.m. | Surgical treatment of cardiac tumors Michael J. Reardon, M.D. |
| 2:00-2:10 p.m. | Questions and Answers: Monika J. Leja, M.D., Michael J. Reardon, M.D.Dipan J. Shah, M.D. |
| 2:10-3:10 p.m. | Session XI: Defining the field of onco-cardiology Moderator: Edward T.H. Yeh, M.D. Panelists: Jean-Bernard Durand, M.D., Richard M. Steingart, M.D., Sandra M. Swain, M.D. |
| 3:10-3:25 p.m. | Break |
| 3:25-5:05 p.m. | Session XI: Hypertension Moderators: Aarif Y. Khakoo, M.D. and Elie N. Mouhayar, M.D. |
| 3:25-3:45 p.m. | Common and uncommon blood pressure issues in cancer patients Elie N. Mouhayar, M.D. |
| 3:45-4:05 p.m. | Renal effects of anti-angiogenic therapy and their relation to hypertension Abdulla Salahudeen, M.D. |
| 4:05-4:25 p.m. . | The role of HIF1 in cardiac function and how anti-VEGF therapy may affect it Javid Moslehi, M.D. |
| 4:25-4:45 p.m. | Guidelines for managing hypertension in patients receiving VEGF inhibitors Michael L. Maitland, M.D., Ph.D. |
| 4:45-5:05 p.m. | Case presentations/panel discussion Ming Hui Chen, M.D., Aarif Y. Khakoo, M.D., Michael L. Maitland, M.D., Ph.D., Javid Moslehi, M.D., Elie N. Mouhayar, M.D., Abdulla Salahudeen, M.D. |
| 5:05-5:10 p.m. | Closing comments Edward T.H. Yeh, M.D. |
Attendance will be limited to 150 participants. 14.00 AMA PRA Category 1 Credits™
For information contact Amy Heaton: aheaton@mdanderson.org or 713-745-6826.
Endorsed By
ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.
Late Breaking News
Key discovered to how chemotherapy drug causes heart failure. See News Release